Cite
HARVARD Citation
Turkova, A. et al. (2022). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet. 9 (9), pp. e627-e637. [Online].